A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance

Trial Profile

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2017 Further analysis of data from this trial published in a Ritter Pharmaceuticals Media Release.
    • 12 Apr 2017 Positive top-line results published in a Ritter Pharmaceuticals media release and full analysis of the data is underway.
    • 28 Mar 2017 Results published in a Ritter Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top